Overview

Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers

Status:
Recruiting

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

This phase I/II trial studies the side effects and best dose of olaparib and entinostat and to see how well they work in treating patients with ovarian, primary peritoneal, or fallopian tube cancers that have come back or do not respond to platinum-based chemotherapy. Olaparib and entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Vanderbilt-Ingram Cancer Center

Collaborators:

AstraZeneca
Syndax Pharmaceuticals

Treatments:

Entinostat
Olaparib